Curs Optional Genetica Medicala Si Biologie Moleculara
Curs Optional Genetica Medicala Si Biologie Moleculara
CURS OPTIONAL
GENETICA MEDICALA SI
BIOLOGIE MOLECULARA
1866
1944
1953
Milestones:
1990: Project initiated as joint effort of U.S. Department of Energy and the National
Institutes of Health
June 2000: Completion of a working draft of the entire human genome
February 2001: Analyses of the working draft are published
April 2003: HGP sequencing is completed and Project is declared finished two years
ahead of schedule
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Organism
Genome Size
(Bases)
Estimated
Genes
3 billion
30,000
2.6 billion
30,000
100 million
25,000
97 million
19,000
137 million
13,000
12.1 million
6,000
4.6 million
3,200
9700
Future Challenges:
What We Still Dont Know
Gene number, exact locations, and functions
Gene regulation
DNA sequence organization
Chromosomal structure and organization
Noncoding DNA types, amount, distribution, information content, and
functions
Coordination of gene expression, protein synthesis, and post-translational
events
Interaction of proteins in complex molecular machines
Proteomes (total protein content and function) in organisms
Correlation of SNPs (single-base DNA variations among individuals) with
health and disease
Disease-susceptibility prediction based on gene sequence variation
Genes involved in complex traits and multigene diseases
Developmental genetics, genomics
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Anticipated Benefits of
Genome Research
Molecular Medicine
improve diagnosis of disease
detect genetic predispositions to disease
create drugs based on molecular information
use gene therapy and control systems as drugs
design custom drugs (pharmacogenomics) based on individual genetic profiles
Microbial Genomics
rapidly detect and treat pathogens (disease-causing microbes) in clinical practice
develop new energy sources (biofuels)
monitor environments to detect pollutants
protect citizenry from biological and chemical warfare
clean up toxic waste safely and efficiently
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Anticipated Benefits of
Genome Research-cont.
Risk Assessment
evaluate the health risks faced by individuals who may be exposed to radiation
(including low levels in industrial areas) and to cancer-causing chemicals and toxins
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Anticipated Benefits of
Genome Research-cont.
DNA Identification (Forensics)
identify potential suspects whose DNA may match evidence left at crime
scenes
exonerate persons wrongly accused of crimes
identify crime and catastrophe victims
establish paternity and other family relationships
identify endangered and protected species as an aid to wildlife officials (could be
used for prosecuting poachers)
detect bacteria and other organisms that may pollute air, water, soil, and food
match organ donors with recipients in transplant programs
authenticate consumables such as caviar and wine
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Anticipated Benefits:
improved diagnosis of disease
earlier detection of genetic predispositions to disease
rational drug design
gene therapy and control systems for drugs
personalized, custom drugs
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
Clinical issues including the education of doctors and other health-service providers,
people identified with genetic conditions, and the general public about capabilities,
limitations, and social risks; and implementation of standards and qualitycontrol
measures.
U.S. Department of Energy Genome Programs, Genomics and Its Impact on Science and Society, 2003
HapMap
Begun in 2002, the project is a 3-year effort to construct
a map of the patterns of SNPs (single nucleotide
polymorphisms) that occur across populations in Africa,
Asia, and the United States.
Consortium of researchers from six countries
Researchers hope that dramatically decreasing the
number of individual SNPs to be scanned will provide a
shortcut for identifying the DNA regions associated with
common complex diseases
Map may also be useful in understanding how genetic
variation contributes to responses in environmental
factors
GWAS(genome wide association study) A genomewide association study (GWAS), also known as whole
genome association study (WGAS), is an
examination of all or most of the genes (the genome)
of different individuals of a particular species to see
how much the genes vary from individual to
individual
MEDICINA GENOMICA
ONCOGENOMICA
Medicina genomica
ONCOGENETICA
Fiecare tumor conine un numr foarte mare de
modificri genetice i epigenetice diverse.
numai un numr mic de mutaii (mai puin de zece),
numite mutaii conductoare (driver mutations) sunt
necesare pentru iniierea clonei canceroase (mutaii
oncogenice) i pentru meninerea/expansiunea
tumoral (mutaii de meninere)
unele mutaii conductoare au fost definite ca modificri
acionabile (actionable aberrations), n sensul c
implic aciuni practice deoarece au impact asupra
managementului cancerului prin utilizarea lor n
diagnostic, prognostic i/sau predicie;
o parte dintre acestea sunt i tratabile(druggable
aberrations) ntruct oncoproteinele codificate pot fi
inta unor noi terapii, care schimb evoluia bolii
ONCOGENETICA
ONCOGENETICA
Astfel, celulele canceroase dezvolt rezisten la
apoptoz, prin activarea unor ci de
supravieuire celular, secundar unor mutaii
(de exemplu, a genei APC n cancerul colorectal
sau a oncogenei KRAS n cancerul pulmonar
fr celule mici);
celulele canceroase cu aceste mutaii pot fi
eliminate prin folosirea unei combinaii sinteticletale
ONCOGENETICA
Un alt exemplu de letalitate sintetic este reprezentat de
celulele canceroase cu mutaii ale genelor de reparare
ale leziunilor ADN (de tipul BRCA1 i BRCA2 n cancerul
ereditar de sn i ovar sau PTEN n cancerul de
prostat).
ONCOGENETICA
leziunile genetice gsite n trunchiul principal
(clona iniial) sunt exprimate i n ramurile
sale (subclone).
n aceste condiii, se impune schimbarea
strategiilor terapeutice i direcionarea lor spre
gen i nu spre proteina codificat de gen,
urmrind inhibiia ei funcional sau restaurarea
structurii ei normale
PROTEOMICA
Analiza de secven poate furniza mai multe date prin compararea secvenei
unei proteine cu cele stocate n bazele de date.
se pot gsi informaii despre: structura, interaciile, activitatea biochimic,
evoluia i chiar rolul potenial ntr-o boal.
TEHNOLOGIA PCR
Din punct de vedere chimic, reacia PCR este constituit din cicluri succesive
de replicare ADN in vitro, folosind 2 primeri oligonucleotidici ce hibridizeaz
cu cele 2 catene ale secvenei originale (folosit ca matri n replicare).
Diferena esenial ntre o asemenea reacie de replicare i un proces de
replicare ADN in vivo, l reprezint faptul c n reacia PCR etapa de
desfacere a dublului helix matri i, respectiv, cea de ataare a primerilor, nu
sunt realizate enzimatic, ci prin parcurgerea unor trepte de temperatur, iar
singura enzim folosit n reacie este o ADN polimeraz ADN-dependent
(cu funcie de replicaz).
TIPURI DE PCR
TELOCIT
Telocitele sunt celule cu corp mic, dar cu prelungiri
extrem de lungi (asemanatoare prelungirilor neuronilor),
prezente in aproape toate organele.
1.
2.
3.
4.
Informatia
epigenetica
determina
modularea
expresiei genice conform unui pattern determinat
de etapa de dezvoltare, de tipul de tesut si de
conditile ambientale determinind un anumit fenotip
celular.
Replicarea cromatinei in cursul fazei S a ciclului
celular ofera oportunitatea factorilor responsabili sa
adauge si sa propage in noua catena ADN toti
markerii epigenetici identificati in celula parentala.
Epigenetica a adus rezultate remarcabile in
optimizarea strategiilor de diagnostic (diagnosticul
timpuriu si preventia) si in elaborarea strategiilor
terapeutice epigenetice.
EPIGENETICA
1. Metilarea ADN
-Adaugarea
Nucleotidele CpG
Distribuite in intreg genomul
Concentrate in regiuni numite insule CpG
(60% din ADN genomic)
Localizate preferential la nivelul:
- promotorului genelor
- regiunilor ADN reglatoare
-ADN repetitiv (palindroame, ADN satelit)
clusterele CpG nemetilate sunt situate in genele
implicate in desfasurarea optima a activitatii
celulare (ex. gene housekeeping).
Pattern-ul de metilare
Conservat in celulele somatice
Realizat de ADN metiltransferaze (DNMT- DNA
methyltransferases)
DNMT1- actioneaza preferential asupra ADN hemimetilat.
-metileaza catenele nou sintetizate imediat
dupa
replicare, folosind matrita parentala.
ADN metiltransferaze de novo:
- DNMT3A
- DNMT3B
. Folate metabolism: folate, along with choline, methionine, cobalamin, pyridoxine, and
riboflavin, is involved in several essential metabolic processes within the cell, in particular
DNA synthesis, repair, and methylation. Folate is also essential as a methyl donor
2. Structura cromatinei
Cromatina- organizata in 2 nivele:
- heterocromatina silentiata
(telomere, regiuni pericentrice,
secvente repetitive)
-eucromatina activa (genele active)
Nucleosom = unitatea de baza a
cromatinei (ADN dublu catenar
infasurat in jurul octamerului histonic).
Lodish, 2000
Modelare
expresie
genica
fenotip
Modularea transcrierii
Acetilarea si metilarea sunt considerate modulatorii
cheie ai activarii si represiei transcriptionale
Codul epigenetic
Fig. 2. (a), aberrant methylation keeps occurring. After several clonal selections during multistep
carcinogenesis, all cancer cells come to have methylation of multiple CGI. In contrast, if a cancer cell is
derived from a precursor cell with methylation of multiple CGI (b), cancer cells
derived from it will also display methylation of multiple CGI.
microARN (miRNA)
Molecule mici de ARN endogen (22 nucleotide),
monocatenar, necodificator
Se leaga la capatul 3 (3UTR) al unui/unor ARN
mesager specific(i)
Moduleaza expresia genica prin
- represarea expresia proteinei tinta
- degradarea ARNm specific
Poate controla direct structura cromatinei tintind factori
implicati in remodelarea acesteia (conexiune cu PcG)
In imunologie, miRNA sunt considerati reglatori cheie
in angajarea pe o linie de diferentiere, maturare,
mentinerea homeostaziei
Biogeneza/ actiune
Istoria miRNA
miRNA in hepatopatii
EXOZOM
Exozomii au markeri de suprafata CD63, CD9, CD81.
Deriva din linie hematopoetica :reticulocite, trombocite si
limfocite .
Pot fi secretati si de celule tumorale epiteliale ( neo
pulmonar, renal, intestinal).
Studii recente au demonstrat ca pot transporta mRNA si
microRNA.